Board Elections, Dividend Authorizations, Leadership Appointments, and Earnings Results - Analyst Notes on CareFusion, Teleflex, Haemonetics, ICU and Tornier

NEW YORK, May 12, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding CareFusion Corporation (NYSE: CFN), Teleflex Incorporated (NYSE: TFX), Haemonetics Corp. (NYSE: HAE), ICU Medical, Inc. (NASDAQ: ICUI) and Tornier N.V. (NASDAQ: TRNX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2294-100free.

--
CareFusion Corporation Analyst Notes
On May 7, 2014, CareFusion Corp. (CareFusion) announced the election of Supratim Bose to the Company's Board of Directors, effective immediately, taking the Board's size to 10 members. "Supratim's deep knowledge and leadership experience in the Asia Pacific and international markets will be a valuable contribution as we look to grow our company outside of the U.S.," said Kieran Gallahue, Chairman and CEO of CareFusion, "We are fortunate to have someone with his credentials in the medical device industry as part of our board of directors." Mr. Bose will serve as an independent director and will also stand for re-election at the Company's annual meeting of stockholders, expected to take place in November 2014. The full analyst notes on CareFusion are available to download free of charge at:

http://www.analystsreview.com/2294-CFN-12May2014.pdf

--
Teleflex Incorporated Analyst Notes
On May 5, 2014, Teleflex Inc. (Teleflex) announced that its Board of Directors has approved and declared a quarterly cash dividend in the amount of $0.34 per share of common stock. The dividend is payable on June 16, 2014 to shareholders of record at the close of business on May 15, 2014. The full analyst notes on Teleflex are available to download free of charge at:

http://www.analystsreview.com/2294-TFX-12May2014.pdf

--
Haemonetics Corp. Analyst Notes
On April 30, 2014, Haemonetics Corp. (Haemonetics) announced the appointment of Kent J. Davies as the Company's President, Global Markets effective May 12, 2014. He will assume responsibility for worldwide oversight of all of the Company's commercial operations, except the Global Plasma business. With a strong command on commercial, operational, financial and change leadership skills, he will also be responsible for business elements representing 70% of Haemonetics' revenue base. Brian Concannon, Haemonetics' President and CEO, commented, "We are delighted that Kent will be joining our team to help us execute our unique blood management vision. He brings a wealth of experience from successful leadership roles with rapidly-growing public and private businesses, and he has had considerable success driving profitable growth in the global markets in which we operate." The full analyst notes on Haemonetics are available to download free of charge at:

http://www.analystsreview.com/2294-HAE-12May2014.pdf

--
ICU Medical, Inc. Analyst Notes
On May 6, 2014, ICU Medical Inc. (ICU) reported its Q1 2014 financial results with revenues of $73.2 million, compared to $74.3 million in Q1 2013. GAAP net income totaled $6.7 million, or $0.43 per diluted share, compared to $8.7 million, or $0.58 per diluted share, in Q1 2013. Vivek Jain, ICU's CEO, said, "Our revenues and profitability in the first quarter were in-line with our expectations with good performance in our direct infusion sales, oncology sales and international. Direct infusion sales were up 3% for the quarter but offset by an expected decline in OEM infusion sales. Oncology sales continued to be strong with approximately 10% growth. International sales grew approximately 10%. Gross margins were 49.2% also in-line with expectations." For full year 2014, the Company anticipates revenue in the range of $285 million to $300 million and GAAP fully diluted EPS in the range of $1.15 to $1.45. The full analyst notes on ICU are available to download free of charge at:

http://www.analystsreview.com/2294-ICUI-12May2014.pdf

--
Tornier N.V. Analyst Notes
On May 6, 2014, Tornier N.V. (Tornier) reported its Q1 2014 financial results with revenue growth of 7.7% YoY to $89.0 million. Adjusted EBITDA was $9.5 million, compared to $9.1 million in Q1 2013. Dave Mowry, President and CEO of Tornier, commented, "We are encouraged by the modest pick-up in our sales growth in the first quarter as we continue to execute phase 2 of our U.S. sales force transition plan. We remain focused on finalizing the alignment to upper and lower extremity product specialization as well as focusing on territory optimization and rep training. During this challenging transition of our U.S. sales channel, we have maintained the focus on our international business which recorded double digit sales growth in the quarter." The Company anticipates Q2 2014 revenue of $76 million to $80 million, in constant currency, and adjusted EBITDA of $3 million to $5 million. The full analyst notes on Tornier are available to download free of charge at:

http://www.analystsreview.com/2294-TRNX-12May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review